The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy

INTRODUCTION: The phase 3 trial PALISADE, comparing peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) oral immunotherapy versus placebo in peanut-allergic children, reported that a significantly higher percentage of PTAH-treated participants tolerated higher doses of peanut protein after 1 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shengsheng, Smith, Alex, Hass, Steve, Wu, Eric, Chai, Xinglei, Zhou, Jenny, Ayyagari, Rajeev, Liu, Jun S., Robison, Dan, Donelson, Sarah M., Tilles, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264172/
https://www.ncbi.nlm.nih.gov/pubmed/34236672
http://dx.doi.org/10.1007/s12325-021-01843-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264172/
https://www.ncbi.nlm.nih.gov/pubmed/34236672
http://dx.doi.org/10.1007/s12325-021-01843-2

Ejemplares similares